GLPG2222 50 mg
Idiopathic Pulmonary Fibrosis
Clinical trials
1
Developer
Lakefront Biotherapeutics NV
Overview
GLPG2222 50 mg is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis. It appears in 1 tracked IPF clinical trial.
GLPG2222 50 mg clinical trials
Explore related
Medical disclaimer. This page summarizes research about GLPG2222 50 mg for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.